|
|
|
|
|
06.07.26 - 14:33
|
Neuronetics to Participate in a Panel Discussion at B. Riley Securities′ Mind, Muscle & Vision Summit on July 16, 2026 (GlobeNewswire EN)
|
|
|
MALVERN, Pa., July 06, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through the Greenbrook network of interventional psychiatry clinics, today announced that management will participate at the B. Riley Securities' Mind, Muscle & Vision Summit, an invitation-only institutional investor event being held in-person at the InterContinental Boston.Neuronetics will participate in a panel discussion titled "Commercializing the Next Wave of Novel Neuropsychiatric Drugs," alongside Compass Pathways, scheduled for Thursday, July 16, 2026. Management will also be available for one-on-one meetings with institutional investors throughout the day.This is an in-person, invitation-only event, and there will be no live webcast of the panel discussion.About NeuroneticsNeuronetics, Inc. is a leader in interventional mental health, combining innovative treatment technologies with direct pa...
|
|
|
|
|
|
|
05.06.26 - 12:36
|
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
|
|
|
LONDON & NEW YORK--(BUSINESS WIRE)--$CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seventeen newly hired non-executive employees. The equity awards were granted on June 1, 2026 and consisted of options to purchase an aggregate of 157,000 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 74,700 shares. The options have an exercise price per share equal to $14.19, the closing price of the Company's American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee's ...
|
|
|
|
|
28.05.26 - 12:36
|
Compass Pathways Elects Kathleen Tregoning to Board of Directors (Business Wire)
|
|
|
LONDON & NEW YORK--(BUSINESS WIRE)--$CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the election of Kathleen Tregoning to its Board of Directors at the annual general meeting of shareholders. Ms. Tregoning is expected to serve on the Compensation and Leadership Development Committee and the Nominating and Corporate Governance Committee. She brings extensive experience guiding biopharmaceutical companies through periods of growth and transformation, with expertise spanning corporate strategy, external affairs, public policy and patient access.
“With two successful Phase 3 trials meeting the primary endpoint, a transformative clinical profile for COMP360, and a rolling NDA submission and review now underway, Compass is strongly positioned to make our goal of securing an FDA approval a reality. Compass is entering a stage where experience in external engagement, public policy...
|
|
|
|
|
|
|
|
|
|
|
13.05.26 - 12:33
|
Compass Pathways Announces First Quarter 2026 Financial Results and Business Highlights (Business Wire)
|
|
|
FDA granted Compass NDA rolling submission and review request, based on strength of Phase 3 data
CNPV awarded for COMP360 in TRD, further accelerating momentum
26-week (Part B) data from COMP006, expected in early Q3 2026
Final NDA submission on track for Q4, aligned with Company's previously defined accelerated timing to be launch ready by end of year
Successful financing and warrant exercises resulted in strong cash position of $466 million at end of first quarter, providing cash runway well beyond launch and into 2028
LONDON & NEW YORK--(BUSINESS WIRE)--$CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported first quarter 2026 financial results and business highlights.
“With regulatory acceleration unfolding, we are working diligently towards our goal of completing the filing of a robust clinical package by Q4 and securing COMP360 approval,” said Kabir Nath, Chief Executive O...
|
|
|
|
|
06.05.26 - 12:36
|
Compass Pathways to Announce First Quarter 2026 Financial Results on May 13, 2026 (Business Wire)
|
|
|
Compass management will host a conference call at 8:00 am ET (1:00 pm UK) LONDON & NEW YORK--(BUSINESS WIRE)--$CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the first quarter ended March 31, 2026, and provide an update on recent developments, on May 13, 2026.
Compass management will host a conference call at 8:00 am ET (1:00 pm UK) on May 13, 2026. A live webcast of the call will be available on the Compass Pathways website at: https://events.q4inc.com/attendee/144892287. The webcast will be archived for 30 days.
About Compass Pathways
Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing trea...
|
|
|
|
|
|
|
|
|
|
|
20.04.26 - 23:54
|
Compass Pathways CEO on Trump′s Order to Expand Psychedelics Research (Bloomberg)
|
|
|
Shares of companies involved in psychedelic-tied therapies surged Monday after President Donald Trump signed an executive order to expedite research and access. US-traded shares of Compass Pathways spiked as much as 53% while AtaiBeckley surged by 37%. GH Research jumped 34% and Definium Therapeutics rallied 16%. The AdvisorShares Psychedelics ETF (PSIL) also climbed as much as 20% — touching its highest intraday level since July 2023. The new order directs the US Food and Drug Administration to issue expedited review vouchers to psychedelics with a so-called breakthrough designation, shortening the review time to one to two months from six to ten months. AtaiBeckley, Definium and Compass Pathways all have therapies with breakthrough status. Compass Pathways CEO Kabir Nath joins Bloomberg Businessweek Daily to discuss. He speaks with Carol Massar and Tim Stenovec. (Source: Bloomberg)...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
